Pharmaceuticals

Small Molecule Targeted Cancer Therapy Industry Anticipated to Expand at 9% CAGR During the Forecast Period

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Small Molecule Targeted Cancer Therapy Market Between 2025 And 2029?

The small molecule targeted cancer therapy market size has seen strong growth in recent years. Its value is projected to climb from $78.07 billion in 2024 to $85.35 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historic period can be credited to an improved understanding of cancer biology, an increase in the approval of inhibitors, a rising prevalence of cancer, the early adoption of personalized medicine, and the expansion of oncology clinical trials.

The small molecule targeted cancer therapy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $120.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.0%. Factors driving this expansion over the forecast period include a heightened demand for precision oncology, increased investment in next-generation inhibitors, escalating healthcare spending in developing economies, a surge in demand for these treatments, and an uptick in strategic partnerships. Key trends emerging during this period encompass an emphasis on tumor-agnostic treatments, the advancement of allosteric modulators, the integration of artificial intelligence into drug discovery processes, the uptake of oral targeted therapies, and a move towards combined treatment approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28331&type=smp

Which Major Market Drivers Are Shaping The Future Of The Small Molecule Targeted Cancer Therapy Market?

The escalating need for personalized medicine is anticipated to fuel the expansion of the small molecule targeted therapy market moving forward. Personalized medicine defines a medical strategy that customizes disease prevention, diagnosis, and treatment based on each patient’s distinct characteristics. The demand for personalized medicine is increasing due to a heightened requirement for targeted treatments that enhance efficacy and diminish adverse effects. Small molecule targeted therapy addresses this demand for personalized medicine by improving treatment specificity, boosting patient response, reducing side effects, and enabling therapies tailored to individual genetic and molecular profiles. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a considerable increase from the six approvals in 2022. Therefore, the rising demand for personalized medicine is propelling the growth of the small molecule targeted therapy market.

What Are The Key Segments In The Small Molecule Targeted Cancer Therapy Market?

The small molecule targeted cancer therapy market covered in this report is segmented as

1) By Therapy Type: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, PARP Inhibitors, CDK Inhibitors, BCL-2 Inhibitors, mTOR Inhibitors, Other Small Molecule Inhibitors

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Cancer Types

3) By Mode Of Administration: Oral, Intravenous, Other Modes

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Sales

5) By End User: Hospitals, Specialty Clinics, Research Institutes, Other End Users

Subsegment:

1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, VEGFR Inhibitors, ALK Inhibitors, BCR-ABL Inhibitors, HER2 Inhibitors

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Pan-Histone Deacetylase Inhibitors, Class-specific Histone Deacetylase Inhibitors

4) By PARP Inhibitors: Olaparib, Niraparib, Rucaparib, Talazoparib

5) By CDK Inhibitors: CDK4/6 Inhibitors, CDK1/2 Inhibitors, Pan-CDK Inhibitors

6) By BCL-2 Inhibitors: Venetoclax, Navitoclax

7) By mTOR Inhibitors: Rapamycin Analogs (Rapalogs), ATP-competitive mTOR Inhibitors, Dual mTOR/PI3K Inhibitors

8) By Other Small Molecule Inhibitors: MEK Inhibitors, PI3K Inhibitors, RAF Inhibitors

What Long-Term Trends Will Shape The Future Growth Of The Small Molecule Targeted Cancer Therapy Industry?

Leading companies in the small molecule targeted cancer therapy market are concentrating on innovative treatments, such as structure-based drug design, to create highly selective inhibitors that specifically target oncogenic mutations, minimize off-target effects, and improve patient outcomes. Structure-based drug design is an approach that leverages the 3D structure of a target protein to engineer small molecules that bind precisely, thereby enhancing drug effectiveness and reducing side effects. For instance, in December 2022, Mirati Therapeutics, a US-based oncology company, announced KRAZATI (adagrasib) as a targeted therapy for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have undergone at least one prior systemic therapy approved by the U.S. Food and Drug Administration (FDA), a US-based government agency. This approval provides a new treatment option for individuals with difficult-to-treat KRAS G12C-mutated non-small cell lung cancer, addressing a significant unmet medical need. KRAZATI operates by selectively inhibiting the KRAS G12C mutant protein, which plays a role in cancer cell proliferation and survival.

Who Are The Primary Competitors In The Global Small Molecule Targeted Cancer Therapy Market?

Major companies operating in the small molecule targeted cancer therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., and Ipsen Biopharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-cancer-therapy-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Small Molecule Targeted Cancer Therapy Market?

North America was the largest region in the small molecule targeted cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small molecule targeted cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Small Molecule Targeted Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28331&type=smp

Browse Through More Reports Similar to the Global Small Molecule Targeted Cancer Therapy Market 2025, By The Business Research Company

Small Molecule Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Rna Targeting Small Molecules Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795